Literature DB >> 9795764

The functional significance of epitope spreading and its regulation by co-stimulatory molecules.

C L Vanderlugt1, W S Begolka, K L Neville, Y Katz-Levy, L M Howard, T N Eagar, J A Bluestone, S D Miller.   

Abstract

Epitope spreading is a process whereby epitopes distinct from and non-cross-reactive with an inducing epitope become major targets of an ongoing immune response. This phenomenon has been defined in experimental and natural situations as a consequence of acute or persistent infection and secondary to chronic tissue destruction that occurs during progressive autoimmune disease. We have investigated the functional significance of this process in the chronic stages of both autoimmune and virus-induced central nervous system (CNS) demyelinating disease models in the SJL/J mouse. During the relapsing-remitting course of experimental autoimmune encephalomyelitis (R-EAE) induced with defined encephalitogenic myelin peptides, CD4+ T cells specific for endogenous epitopes on both the initiating myelin protein (intramolecular epitope spreading) and distinct myelin proteins (intermolecular epitope spreading) are primed secondary to myelin destruction during acute disease and play a major functional role in mediating disease relapses. Similarly, epitope spreading to endogenous myelin epitopes appears to play a major functional role in the chronic-progressive course of Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD), a virus-induced CD4+ T-cell-mediated immunopathology. In TMEV-IDD, myelin destruction is initiated by virus-specific CD4+ T cells which target virus epitopes persisting in CNS-derived antigen-presenting cells. However, the chronic stage of this progressive disease is associated with the activation of CD4+ T cells specific for multiple myelin epitopes. In both models, the temporal course of T-cell activation occurs in a hierarchical order of epitope dominance, spreading first to the most immunodominant epitope and progressing to lesser immunodominant epitopes. In addition, epitope spreading in R-EAE is regulated predominantly by CD28/B7-1 co-stimulatory interactions, as antagonism of B7-1-mediated co-stimulation using anti-B7-1 F(ab) fragments is an effective ameliorative therapy for ongoing disease. The process of epitope spreading has obvious important implications for the design of antigen-specific therapies for the treatment of autoimmune disease since these therapies will have to identify and target endogenous self epitopes associated with chronic tissue destruction.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9795764     DOI: 10.1111/j.1600-065x.1998.tb01208.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  56 in total

Review 1.  New animal models to probe brain tumor biology, therapy, and immunotherapy: advantages and remaining concerns.

Authors:  L A Lampson
Journal:  J Neurooncol       Date:  2001-07       Impact factor: 4.130

2.  CD28 costimulatory blockade exacerbates disease severity and accelerates epitope spreading in a virus-induced autoimmune disease.

Authors:  K L Neville; M C Dal Canto; J A Bluestone; S D Miller
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 3.  Have we overestimated the benefit of human(ized) antibodies?

Authors:  Daniel R Getts; Meghann T Getts; Derrick P McCarthy; Emily M L Chastain; Stephen D Miller
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857

Review 4.  Tolerogenic vaccines: Targeting the antigenic and cytokine niches of FOXP3+ regulatory T cells.

Authors:  Mark D Mannie; Kayla B DeOca; Alexander G Bastian; Cody D Moorman
Journal:  Cell Immunol       Date:  2020-07-15       Impact factor: 4.868

5.  Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity.

Authors:  Hitoshi Suzuki; Run Fan; Zhixin Zhang; Rhubell Brown; Stacy Hall; Bruce A Julian; W Winn Chatham; Yusuke Suzuki; Robert J Wyatt; Zina Moldoveanu; Jeannette Y Lee; James Robinson; Milan Tomana; Yasuhiko Tomino; Jiri Mestecky; Jan Novak
Journal:  J Clin Invest       Date:  2009-05-26       Impact factor: 14.808

6.  DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model.

Authors:  Doris Lambracht-Washington; Bao-Xi Qu; Min Fu; Todd N Eagar; Olaf Stüve; Roger N Rosenberg
Journal:  JAMA       Date:  2009-10-28       Impact factor: 56.272

Review 7.  Glioblastoma antigen discovery--foundations for immunotherapy.

Authors:  Tej D Azad; Seyed-Mostafa Razavi; Benjamin Jin; Karen Lee; Gordon Li
Journal:  J Neurooncol       Date:  2015-06-05       Impact factor: 4.130

8.  Retinal S-antigen Th1 cell epitope mapping in patients with Behcet's disease.

Authors:  Changlin Zhao; Peizeng Yang; Hao He; Xiaomin Lin; Liping Du; Hongyan Zhou; Aize Kijlstra
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-10-29       Impact factor: 3.117

9.  Signal transduction inhibition of APCs diminishes th17 and Th1 responses in experimental autoimmune encephalomyelitis.

Authors:  Mario Skarica; Tianhong Wang; Erin McCadden; David Kardian; Peter A Calabresi; Donald Small; Katharine A Whartenby
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

Review 10.  Immune response to FVIII in hemophilia A: an overview of risk factors.

Authors:  Kanjaksha Ghosh; Shrimati Shetty
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.